1Final 1626.

Please type a plus sign (+) inside this box → [+]

RPTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/549,545
Filing Date	May 26, 2006
First Named Inventor	Matteucci
Group Art Unit	1626
Examiner Name	Unassigned
Attorney Docket Number	021305-003900US

Total Number of Pages in This Submission: 7

ENCLOSURES *(check all that apply)*

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment / Response
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Assignment Papers *(for an Application)*
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s)
- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group *(Appeal Notice, Brief, Reply Brief)*
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) *(please identify below)*:
  1) **Return receipt postcard**
  2) **Twenty-Nine (29) references**

Remarks: The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.
Total number of pages does not include cited references.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP Randolph Ted Apple Reg No. 36,429
Signature	
Date	November 16, 2006

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: November 17, 2006

Typed or printed name	Christopher R. Fitting		
Signature		Date	November 17, 2006

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60918787

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On 11/17/06

TOWNSEND and TOWNSEND and CREW LLP

By: _____



PATENT
Attorney Docket No.: 021305-003900US
Client Reference No.: 006-033-US14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Confirmation No.: 1659
Mark MATTEUCCI et al.	Examiner: Unassigned
Application No.: 10/549,545	Art Unit: 1626
Filed: May 26, 2006	INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and §1.98
For: COMPOSITIONS AND METHODS FOR TREATING CANCER	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant

information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Randolph Ted Apple
Reg. No. 36,429

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RTA:crf
60917705 v1

PTO/SB/08A (07-06)

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	10/549,545
Filing Date	May 26, 2006
First Named Inventor	Matteucci, Mark
Art Unit	1626
Examiner Name	Unassigned
Attorney Docket Number	021305-003900US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,855,695	02-15-2005	Xu et al.	
	AB	US-6,656,926	12-02-2003	Borch et al.	
	AC	US-6,251,933	06-26-2001	Denny et al.	
	AD	US-6,130,237	10-10-2000	Denny et al.	
	AE	US-6,020,315	02-01-2000	Bosslet et al.	
	AF	US-5,985,909	11-16-1999	Denny et al.	
	AG	US-5,877,158	03-02-1999	Bosslet et al.	
	AH	US-5,872,129	02-16-1999	Denny et al.	
	AI	US-5,780,585	07-14-1998	Anlezark et al.	
	AJ	US-5,750,782	05-12-1998	Denny et al.	
	AK	US-5,703,080	12-30-1997	Nakakura et al.	
	AL	US-5,622,936	04-22-1997	Wiessler et al.	
	AM	US-5,472,956	12-05-1995	Borch et al.	
	AN	US-5,403,932	04-04-1995	Borch et al.	
	AO	US-5,306,727	04-26-1994	Borch et al.	
	AP	US-5,190,929	03-02-1993	Borch et al.	
	AQ	US-4,921,963	05-01-1990	Skov et al.	
	AR	US-4,908,356	03-13-1990	Borch et al.	
	AS	US-3,652,579	03-28-1972	Hoffer et al.	
	AT	US-2005/0043244 A1	02-24-2005	Lin et al.	
	AU	US-2004/0254103 A1	12-03-2004	Xu et al.	
	AV	US-2004/0176332 A1	09-09-2004	Borch et al.	
	AW	US-2004/0121940 A1	06-24-2004	De Groot et al.	
	AX	US-2003/0130189 A1	07-10-2003	Sender et al.	
	AY	US-2003/0096743 A1	05-22-2003	Sender et al.	
	AZ	US-2003/0050331 A1	03-13-2003	Ng et al.	
	BA	US-2003/0008850 A1	01-09-2003	Borch et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (07-06)

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number	10/549,545
Filing Date	May 26, 2006
First Named Inventor	Matteucci, Mark
Art Unit	1626
Examiner Name	Unassigned
Attorney Docket Number	021305-003900US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		Country Code[3]	Number[4]	Kind Code[5] (*if known*)				
	BB	DE	2229223		02-15-1973			☐
	BC	EP	648 503	A1	04-19-1995			☐
	BD	WO	04/85421	A2	10-07-2004			☐
	BE	WO	04/85361	A1	10-07-2004			☐
	BF	WO	02/96910	A1	12-05-2002			☐
	BG	WO	00/64864	A1	11-02-2000			☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 4

Complete if Known	
Application Number	10/549,545
Filing Date	May 26, 2006
First Named Inventor	Matteucci, Mark
Art Unit	1626
Examiner Name	Unassigned
Attorney Docket Number	021305-003900US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	BH	BERRY et al., "5-Nitrofuran-2-ylmethyl group as a potential bioreductively activated pro-drug system," J. Chem. Soc. Perkin Trans., 1:1147-1156 (1997).	☐
	BI	BORCH et al., "Synthesis and Evaluation of Nitroheterocyclic Phosphoramidates as Hypoxia-Selective Alkylating Agents," J. Med. Chem., 43:2258-2265 (2000).	☐
	BJ	BORCH et al., "Antitumor Activity and Toxicity of Novel Nitroheterocylic Phosphoramidates," J. Med. Chem., 44:74-77 (2001).	☐
	BK	DE GROOT et al., "Anticancer Prodrugs for Application in Monotherapy: Targeting Hypoxia, Tumor-Associated Enzymes, and Receptors," Current Medical Chemistry, 8:1093-1122 (2001).	☐
	BL	DE JAEGER et al., "Relationship of hypoxia to metastatic ability in rodent tumours," Br. J. Cancer, 84(9):1280-1285 (2001).	☐
	BM	ENGLE et al., "^{31}P NMR Kinetic Studies of the Intra- and Intermolecular Alkylation Chemistry of Phosphoramide Mustard and Cognate N-Phosphorylated Derivatives of *N*,*N*-Bis(2-chlorethyl)amine[1,2]," J. Med. Chem., 25:1347-1357 (1982).	☐
	BN	EVERETT et al., "Modifying rates of reductive elimination of leaving groups from indolequinone prodrugs: a key factor in controlling hypoxia-selective drug release," Biochemical Pharmacology, 63:1629-1639 (2002).	☐
	BO	EVERETT et al., "Bioreductively-Activated Prodrugs for Targeting Hypoxic Tissues: Elimination of Aspirin from 2-Nitroimidazole Derivatives," Biooganic Med. & Chem. Ltrs., 9:1267-1272 (1999).	☐
	BP	HAY et al., "A 2-Nitroimidazole Carbamate Prodrug of 5-Amino-1-(Chloromethyl)-3-[(5,6,7-Trimethoxyindol-2-YL)Carbonyl]-1,2-Dihydro-3*H*-Benz[E]Indole (Amino-*Seco*- CBI-TMI) for Use With Adept and Gdept," Biooganic Med. & Chem. Ltrs., 9:2237-2242 (1999).	☐
	BQ	HAY et al., "Structure-Activity Relationships of 1,2,4-Benzotriazine 1,4-Dioxides as Hypoxia-Selective Analogues of Tirapazamine," J. Med. Chem., 46:169-182 (2003).	☐
	BR	HERNICK et al., "Design, Synthesis, and Biological Evaluation of Indolequinone Phosphoramidate Prodrugs Targeted to DT-diaphorase," J. Med. Chem., 45:3540-3548 (2002).	☐
	BS	HERNICK et al., "Studies on the Mechanisms of Activation of Indolequinone Phosphoramidate Prodrugs," J. Med. Chem., 46:148-154 (2003).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	10/549,545
Filing Date	May 26, 2006
First Named Inventor	Matteucci, Mark
Art Unit	1626
Examiner Name	Unassigned
Attorney Docket Number	021305-003900US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	BT	KYLE et al., "Direct Assessment of Drug Penetration into Tissue Using a Novel Application of Three-Dimensional Cell Culture," Cancer Research, 64:6304-6309 (2004).	☐
	BU	LIN et al., "(*o*- and *p*- Nitrobenzyloxycarbobyl) -5-fluorouracil Derivatives as Potential Conjugated Bioreductive Alkylating Agents," J. Med. Chem., 29:84-89 (1986).	☐
	BV	NAYLOR et al., "Recent Advances in Bioreductive Drug Targeting," Mini Reviews in Med. Chem., 1:17-29 (2001).	☐
	BW	PAPOT et al., "Design of Selectively Activated Anticancer Prodrugs: Elimination and Cyclization Strategies," Curr. Med. Chem. - Anti-Cancer Agents, 2:155-185 (2002).	☐
	BX	PARVEEN et al., "2-Nitroimidazol-5-Ylmethyl as a Potential Bioreductively Activated Prodrug System: Reductively Triggered Release of the Parp Inhibitor 5-Bromoisoquinolinone," Biooganic Med. & Chem. Ltrs., 9:2031-2036 (1999).	☐
	BY	ROFSTAD et al., "Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis," Br. J. Cancer, 80(11):1697-1707 (1999).	☐
	BZ	ROSEN et al., "Phase 1 Study of TLK286 (Telcyta) Administered Weekly in Advanced Malignancies," Clin. Cancer Res., 10:3689-3698 (2004).	☐
	CA	STEINBERG et al., "Synthesis and Evaluation of Pteroic Acid-Conjugated Nitroheterocyclic Phosphoramidates as Folate Receptor - Targeted Alkylating Agents," J. Med. Chem., 44:69-73 (2001).	☐
	CB	WAKSELMAN, M., "1,4- and 1,6- Eliminations from Hydroxy- and Amino-Substituted Benzyl Systems: Chemical and Biochemical Applications," Nouv. J. Chim., 7(7):439-447 (1983).	☐
	CC	WEST et al., "A comparison of adriamycin and mAMSA, II. Studies with V79 and human tumour multicellular spheroids," Cancer Chemother. Pharmacol., 20:109-114 (1987).	☐
	CD	WORKMAN et al., "The experimental development of bioreductive drugs and their role in cancer therapy," Cancer and Metastasis Rev., 12:73-82 (1993).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.